Related Experiment Video
Updated: Apr 24, 2026
10:42
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
8.4K
Cyclic peptide-selenium nanoparticles as drug transporters
Amir Nasrolahi Shirazi1, Rakesh K Tiwari, Donghoon Oh
1Chao Family Comprehensice Cancer Center, School of Medicine, University of California, Irvine , Shanbrom Hall, 101 The City Drive South, Orange, California 92868, United States.
Molecular Pharmaceutics
|September 4, 2014
Summary
A novel cyclic peptide synthesized selenium nanoparticles (CP-SeNPs) for drug delivery. These nanoparticles significantly enhanced cellular uptake and anticancer drug efficacy in leukemia and ovarian cancer cells.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Cyclic peptides offer unique structural properties for nanomaterial synthesis.
- Selenium nanoparticles (SeNPs) have garnered interest for biomedical applications.
- Developing efficient delivery systems for biomolecules and anticancer drugs remains a challenge.
Purpose of the Study:
- To synthesize cyclic peptide-capped selenium nanoparticles (CP-SeNPs) using a W5R4C peptide.
- To evaluate the potential of W5R4C-SeNPs as a delivery vehicle for biomolecules and anticancer drugs.
- To assess the impact of W5R4C-SeNPs on cellular uptake and the antiproliferative activity of various anticancer agents.
Main Methods:
- Synthesis of a W5R4C cyclic peptide and its subsequent reaction with SeO3(-2) to form W5R4C-SeNPs.
- Characterization of W5R4C-SeNPs using transmission electron microscopy (TEM).
- Evaluation of cellular uptake of fluorescence-labeled phosphopeptide and dasatinib in CCRF-CEM and SK-OV-3 cells using flow cytometry and confocal microscopy.
- Assessment of the antiproliferative effects of W5R4C-SeNPs in combination with various anticancer drugs on SK-OV-3 cells.
Main Results:
- W5R4C-SeNPs were successfully synthesized, with sizes ranging from 110-150 nm.
- Cellular uptake of a phosphopeptide and dasatinib increased significantly (25- and 9-fold, respectively) in the presence of W5R4C-SeNPs.
- Co-administration with W5R4C-SeNPs enhanced the antiproliferative activity of 10 different anticancer drugs against SK-OV-3 cells by 17-49%.
Conclusions:
- W5R4C-SeNPs demonstrate potential as effective nanosized delivery tools.
- These CP-SeNPs can facilitate the delivery of negatively charged biomolecules and anticancer drugs.
- The findings suggest a promising role for CP-SeNPs in cancer therapy and drug delivery applications.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
156
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
156
01:24Modified-Release Drug Delivery Systems: Site-Targeted
160
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160